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Abstract There is a significant unmet need for safe, anabol-
ic muscle therapies to treat diseases and conditions associat-
ed with severe muscle weakness and frailty. The identifica-
tion of such therapies requires appropriate cell-based screen-
ing assays to select compounds for further development
using animal models. Primary human skeletal muscle cells
have recently become available from a number of commer-
cial vendors. Such cells may be valuable for studying the
mechanisms that direct muscle differentiation, and for iden-
tifying and characterizing novel therapeutic approaches for
the treatment of age- and injury-induced muscle disorders.
However, only limited characterization of these cells has
been reported to date. Therefore, we have examined four
primary human muscle cell preparations from three different
vendors for their capacity to differentiate into multinucleated
myotubes. Two of the preparations demonstrated robust
myotube formation and expressed characteristic markers of
muscle differentiation. Furthermore, these myotubes could
be induced to undergo morphological atrophy- and
hypertrophy-like responses, and atrophy could be blocked
with an inhibitor of myostatin signaling, a pathway that is
known to negatively regulate muscle mass. Finally, the
myotubes were efficiently infected with recombinant adeno-
virus, providing a tool for genetic modification. Taken to-
gether, our results indicate that primary human muscle cells
can be a useful system for studying muscle differentiation,
and may also provide tools for studying new therapeutic
molecules for the treatment of muscle disease.
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Introduction
Age- or injury-induced muscle weakness leading to frailty is
a major public health problem that is predicted to escalate in
the future as the number and proportion of older adults
increase in the general population (Berger and Doherty
2010). There is an unmet need for therapeutic strategies that
can slow the effects of aging on muscle function in the frail
elderly so as to maintain or improve their quality of life.
Identifying suitable therapeutic targets and testing candidate
drugs for the ability to improve muscle function require cell-
based model systems that reliably predict in vivo effects in
both pre-clinical rodent models and human patients. A num-
ber of useful rodent cell lines such as mouse C2C12 or rat L6
myoblasts are available (Sultan et al. 2006). These cell lines,
and others, have been used extensively to explore the mo-
lecular mechanisms of muscle differentiation and function
(McFarlane et al. 2006; Cui et al. 2009). In addition, they
have been used in some drug discovery screens (Baudy et al.
2009; Cho et al. 2009). However, because immortalized cell
lines often are genetically abnormal, and have been
maintained under artificial conditions in culture for very long
periods of time which can cause them to deviate from normal
function, a potentially more predictive screening strategy
would use primary human muscle cells. Such cells have
recently become available from a number of commercial
vendors, but only limited characterization of these various
primary cells has been reported (Janowski 2011). Therefore,
we examined several primary human skeletal muscle cell
preparations from different vendors and characterized each
for their capacity to reproducibly differentiate into multinu-
cleated myotubes. Those that reproducibly differentiated into
myotubes were further examined for the expression of
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various markers of skeletal muscle cells such as Myogenic
Differentiation-1 (MYOD), Myocyte enhancer factor 2C
(Mef2C), Myogenin (MYOG), Troponin T type 1 (TNNT),
and Myosin heavy chain-2 (MYH2). We also tested known
inducers of skeletal muscle atrophy (myostatin and dexameth-
asone) and hypertrophy (insulin-like growth factor-1) for effects
on the differentiated myotubes derived from the primary cells.
In addition, we found that myostatin-induced activity on the
myotubes can be blocked by treatment with a soluble myostatin
receptor, similar to one that is currently in clinical trials for
diseases associated withmuscle wasting (Lee et al. 2005; Pistilli
et al. 2011). Finally, we show that both the undifferentiated
primary muscle cells as well as the myotubes they give rise to
can be infected with adenovirus. This observation suggests the
potential for using these cells in genetic screens (both over-
expression and knock-down) to identify factors that play a role
in muscle differentiation and function. Such factors may pro-
vide novel targets for future drug development.
Materials and Methods
Cells, media, and supplement HSMM (catalog #CC-2580,
Lot# 6F4528, sourced from quadriceps muscle of a 16-yr-old
male cadaver) and SkMC-L (catalog #CC-2561, Lot#
6F3791, sourced from human fetal skeletal muscle) were
purchased from Lonza (Walkersville, MD). SkMDC (catalog
#SK-1111, Lot# P101014-50M2, sourced from rectus
abdominus muscle of a 50-yr-old male Caucasian with a Body
Mass Index (BMI) of 21, non-diabetic, smoker for 20 yr) came
from Cook Myosite (Pittsburgh, PA). SkMC-P (catalog #C-
12530, Lot# 8121902.17, sourced from unspecified skeletal
muscle of a 21-yr-old male Caucasian) was obtained from
PromoCell (Heidelberg, Germany). Vendors also supplied
growth media with supplements and serum for their respective
cells. HSMM differentiation medium was prepared by adding
2% horse serum to DMEM-F12 medium (both from
Invitrogen, Grand Island, NY). The vendor stated that HSMM
would differentiate in all horse serum lots, so no pre-screening
was required. SkMDC differentiation medium (ready to use)
was supplied by the vendor (Catalog # MD-5555). Recombi-
nant humanMyostatin (Mstn) and ActRIIb-Fc were generated
in-house as previously described (Thies et al. 2001; Lee et al.
2005). Recombinant human IGF-1 and TWEAK were pur-
chased from R&D Systems (Minneapolis, MN), while Dex
was obtained from Sigma (St. Louis, MO).
Cell culture and differentiation HSMM and SkMDC were
maintained in growth medium with supplements and fetal
bovine calf (FBS) serum provided by the vendors. Cultures
were expanded and frozen stocks were prepared following
the vendors’ instructions. SkMDC were passaged when they
reached 50% confluence, (about every 2–3 d). When
passaging, the culture medium was warmed to 37°C and
the cells were seeded at 5,000–7,500 cells/cm2 and incubated
in a humidified incubator at 37°C, 5% CO2. Culture medium
was changed every other day. HSMM were passaged when
they reached 50–70% confluency (about every 3 d). The
culture conditions for these cells were the same as those for
SkMDC except they were seeded at 3,500 cells/cm2. For
both cell types, cultures were used for experiments after no
more than seven population doublings because the cells’ rate
of differentiation declined after higher population doublings.
To induce differentiation, cells were plated at 20,000-
cells/cm2 in 12-well polystyrene cell culture plates (VWR)
and incubated overnight in growth medium in a cell culture
incubator (37°C, 5% CO2). The following morning, the
growth medium was replaced with differentiation medium
and the cultures were incubated for 3 d, during which time
myotube differentiation occurred. To examine effects on
differentiation, agents to be tested were added at the time
of medium change and cultured for 3 d. To examine effects
on differentiated myotubes, agents to be tested were added
on day 3 of differentiation, after myotube formation had
occurred, and then cultures were incubated for another 2–
3 d. For analysis, to unambiguously identify myotubes, the
cultures were fixed and immuno-stained with an antibody
against Myosin Heavy Chain-2 protein (MYH2), as de-
scribed below.
Immunostaining and fluorescence analysis Cells were stained
for Myosin Heavy Chain-2 protein (MYH2) as follows. Cells
were fixed with 10% formalin for 20 min at room tempera-
ture (RT). Following 2–3 rinses with PBS, cells were perme-
abilized with 0.5% Triton X-100 (Sigma) in PBS for 15 min
at RT. Non-specific binding was blocked with 2% BSA
(Sigma), 0.25% Triton X-100 in PBS at RT for 30 min. Cells
were then incubated with anti-skeletal myosin FAST primary
antibody, MY-32 (Sigma), diluted 1:200 in blocking buffer
for 2 h at RT. After rinsing with blocking buffer without
Triton 2 times for 10 min each, cells were incubated with
Alexa 488 (green) or Alexa 555 (red) conjugated anti-Mouse
IgG secondary antibodies (both from Invitrogen) at 1:400
dilution along with Hoechst nuclear stain (#33342; Sigma) at
1:5,000 dilution in blocking buffer at RT for 1 h. Finally,
cells were washed with PBS 3 times, 5 min each, before
mounting with Vectashield containing Hoechst stain. All
imaging was performed with a Nikon Eclipse Ti-S. Images
were processed with NIS-Elements BR 3.10 software (Micro
Video Instruments, Avon, MA). For quantitative analysis of
immuno-stained samples, total myotube area was calculated
as described in Semsarian et al. (1999) and Lecomte et al.
(2010). Briefly, 5 images were captured from each of 3
replicate wells for each treatment group, for a total of 15
images per condition. A fluorescence intensity threshold was
set such that only the MYH2-positive areas were measured
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by the software. The mean area for the untreated group
(media only) was used to calculate the percent increase or
decrease in myotube area for each treatment. This method
allows a relatively rapid assessment of a compound’s effect
on myotube size.
Western blot analysis For Western blot analyses, antibodies
against phosphorylated-Smad2 (ser465/467) (pSmad2),
Smad2, phosphorylated-Akt (ser473) (pAKT), Akt, and
alpha-tubulin were purchased from Cell Signaling Technolo-
gies (Danvers, MA). They were detected with peroxidase-
labeled goat anti-rabbit IgG from Pierce (Rockford, IL).
Cells were washed in ice cold PBS before lysis in a buffer
comprised of 40 mM MOPS pH 7, 4 mM EGTA, 10 mM
EDTAwith 2% Triton X-100, containing protease and phos-
phatase inhibitors (30 mM sodium fluoride, 60 mM β-
glycerophosphate, 20 mM sodium pyrophosphate, 1 mM so-
dium orthovanadate, and 1% protease inhibitor cocktail, plus
1 mM phenylmethylsulfonylfluoride (PMSF), all from Sigma.
Cell lysates were centrifuged at 15,000 rpm for 10 min at 4°C.
Supernatants were collected and protein contents were mea-
sured using the DC protein assay fromBiorad (Hercules, CA).
Samples were diluted in SDS-PAGE sample buffer and dena-
tured for 5 min at 95°C. Equal amounts of protein were loaded
per lane on 10% Bis–Tris for NuPAGE gels, Invitrogen,
electrophoresed, and then transferred on to nitrocellulose
membranes. Membranes were blocked in Tris-buffered saline
with 0.1% Tween −20 (TBS-T) with 5% (wt/vol) non-fat milk
powder. Primary antibodies were diluted in TBS-T with 5%
BSA and secondary antibodies were diluted in TBS-Twith 5%
non-fat milk. Immuno-reactivity was detected by SuperSignal
West Pico Chemiluminescent substrate (Thermo Scientific,
Rockford, IL) and exposed to film.
RNA analysis RNAwas isolated using an RNeasy kit (Qiagen,
Valencia, CA), following the manufacturer’s protocol.
Quantitative real-time PCR (RT-PCR) was performed using
an Applied Biosystems 7900 HT Fast Real-Time PCR Sys-
tem. The human Taqman probe sets for myosin heavy chain,
MYH2 (Hs00430042_m1), Troponin T type 1, TNNT
(Hs00162848_m1), myocyte enhancer factor 2C, Mef2C
(Hs00231149_m1), myogenic differentiation 1, MYOD
(Hs00159528_m1), myogenin, MYOG (Hs01072232_m1),
and beta-2 microglobulin, B2M (#4333766F), were purchased
from Applied Biosystems (Wilmington, DE).
Adenoviral infection An adenovirus expressing GFP (adeno-
GFP) was purchased from ViraQuest (North Liberty, IA)
(VQAd CMV eGFP titer: 5.0×1010 PFU/mL). For infection
of myotubes, undifferentiated cells were plated at 20,000-
cells/cm2 into 96-well polystyrene cell culture plates and
incubated overnight in growth medium and then switched to
differentiation medium. After myotubes appeared (2–3 d),
infection with adeno-GFP was performed. Several different
ratios of viral particles to cells were tested (Multiplicity of
Infection, or MOI, of 100, 250, 500, 700, and 1,000). In-
fections were performed in growth medium and incubated
with the cells overnight (18 h). The following morning, this
medium was removed and replaced with fresh growth medi-
um and the cells were cultured for an additional 6 h before
switching back to differentiation medium for 48 h. The cells
were then fixed for immuno-staining and visualization of GFP.
For infection of undifferentiated cells, the cells were plat-
ed at 20,000 cells/cm2 in 96-well tissue culture plates and
incubated for 24 h in growth medium. For infection, the
same MOIs and procedure described above were utilized.
In some cases, to observe the effects of infection on myotube
differentiation, cells were returned to differentiation medium
for 6 d after a 6 h recovery period in growth medium.
Statistical analysis Results are expressed as means±-
standard deviations. All data analysis was performed using
Microsoft Excel 2007. Comparisons between two groups
were performed using an unpaired Student’s t test. All tests
were considered significant when p<0.05.
Results
Primary human skeletal muscle myoblasts differentiate into
multinucleated myotubes in culture Four different primary
human muscle cell preparations from three different com-
mercial vendors were screened for the ability to differentiate
into multinucleated myotubes in cell culture. We tested hu-
man skeletal muscle myoblasts (HSMM; Lonza), human
skeletal muscle cells (SkMC-L; Lonza), human skeletal
muscle-derived cells (SkMDC; Cook Myosite), and human
skeletal muscle cells (SkMC-P; PromoCell). Initial experi-
ments found that two of these preparations (SkMC-L and
SkMC-P) showed little, if any, evidence of morphological
differentiation into myotubes when cultured according to the
recommendations of the suppliers. In addition, SkMC-P
grew very poorly as undifferentiated cells in growth medium.
However, HSMM and SkMDC demonstrated robust myotube
differentiation, and could be readily cultured as undifferenti-
ated cells in growth medium, using polystyrene cell culture
plates. Thus, we focused on these two primary cell prepara-
tions for the remainder of our studies presented here. HSMM
were provided as a stock of myoblasts cryopreserved at pas-
sage 2 and characterized by the vendor to display greater than
60% desmin-positive cells at first passage out of cryopreser-
vation. SkMDC were characterized as displaying 92%
desmin-positive cells and a gene expression analysis provided
by the vendor showed that these cells expressed several
markers of muscle cell precursors such as Pax3, Pax7,
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MYOD1, MYOG, and Myf5. Also SkMDC did not express
MYH2 as myoblast cultures. This marker analysis therefore
suggests that the SkMDC population is a committed myoblast
cell population. For both HSMM and SkMDC, the vendors
recommend that these cell populations should be used for
experiments at a population doubling (PD) less than 10. In
our initial studies, we evaluated cell growth and differentiation
of cells through 15 PDs. SkMDC had a PD time of 24 h for up
to 4–5 passages, after which their doubling time slowed
gradually until 15 PDs were reached. HSMM were slower to
recover from cryopreservation compared to SKMDC. For the
first 5 d, their PD time was approximately 40 h, after which it
decreased to 24 h for about 7 d and then increased to 48 h up to
15 PDs. In general, above 10 PDs, both cell types took longer
to differentiate and their differentiation was not as robust,
compared to cells at PD<10 (data not shown). For the studies
described in this paper, we used cells that had undergone no
more than 7 PD. Cells were also plated on several different
extracellular matrix protein (ECM)-coated culture plates to
assess their effect on cell growth and differentiation. The
following human ECMs were screened using Millipore’s
Millicoat ECM-coated strips: fibronectin, vitronectin, laminin,
collagen type I, and collagen type IV. In addition, we also
screened BD PureCoat Amine (BD Biosciences, San Jose,
CA) and polystyrene plates coated in-house with 2% gelatin
(Sigma). No obvious improvement in cell growth or differen-
tiation was detected with any of these matrices compared to
regular tissue-culture treated polystyrene plates. Therefore,
standard cell-culture grade polystyrene plates were used
throughout these studies.
Both HSMM and SkMDC differentiated into myosin
heavy chain (MYH2)-positive multinucleated myotubes
within 3 d when cultured on polystyrene cell culture plates
in differentiation medium (Fig. 1A). In general, the undiffer-
entiated cells cultured in growth medium did not express
MYH2, although occasional MYH2-positive cells were seen
in growing cultures, possibly resulting from cell confluence
associated contact-dependent cell differentiation (see
SkMDC in Fig. 1A). To minimize this issue, care was taken
to subculture growing cultures of cells before they became
confluent. It was noted that the organization of nuclei within
the myotubes was different between HSMM and SkMDC. In
HSMMmyotubes, the nuclei tend to be arranged as singlets,
or small groups, in linear arrays. In contrast, the nuclei in
SkMDC myotubes were often clustered together in large
groups (Fig. 1A). This difference may be caused by differ-
ences in the mechanisms of cell fusion during myotube
generation, or by differences in the regulation of nuclear
dynamics in the myotubes, or other unknown factors. To
further characterize the differentiation process of HSMM
and SkMDC, RNA was prepared from cells harvested on
day 0 through day 6 of culture in differentiation medium.
Gene expression analyses were performed using quantitative
RT-PCR for various markers of muscle cell differentiation,
(Fig. 1B). In all cases, gene expression levels were normal-
ized to beta-2 microglobulin (B2M) expression levels in
order to assess changes in relative expression. MyoD and
Mef2C, transcription factors that play important roles in
specifying the myogenic lineage, represent two early
markers of myoblast differentiation into myotubes (Megeney
and Rudnicki 1995; Black and Olson 1998; Zammit et al.
2006). In both HSMM and SkMDC, there was a transient,
modest upregulation of MyoD at day 1 (although it was
statistically significant for HSMM only) which returned to
baseline levels by day 2. Mef2C was also upregulated by
day 1 in both cell populations, reaching statistical signifi-
cance by day 2, but unlike MyoD, the expression of this gene
remained elevated throughout the 6-d culture period.
Myogenin (MYOG), Troponin T (TNNT), and MYH2 rep-
resent late markers of muscle cell differentiation (Burattini
et al. 2004; Ozernyuk and Balan 2007). Similar expression
trends with these markers were seen in HSMM and SkMDC
cultures. MYOG was upregulated approximately tenfold by
day 1 of differentiation and that expression level remained
significantly elevated from day 2 to day 6 of culture. TNNT
was significantly upregulated by day 1 of differentiation in
HSMM and by day 2 of differentiation for SkMDC. TNNT
expression remained at least tenfold upregulated through
day 6 of differentiation in both cell populations. MYH2
was also expressed at least fivefold above control expression
levels by day 1 of differentiation for HSMM and by day 2 of
differentiation for SkMDC. Then, MYH2 expression reached
greater than tenfold above control levels through day 6 of
differentiation. Thus, HSMM and SkMDC undergo morpho-
logical differentiation in culture into multinucleated myotubes
and express characteristic molecular markers of muscle cell
differentiation.
Induction of morphological atrophy and hypertrophy Dexa-
methasone, a synthetic steroid, and myostatin, a growth
factor which is a negative regulator of muscle mass, are
well-characterized inducers of myotube atrophy, as shown
for C2C12 myotubes (Lee 2004; Stitt et al. 2004). Also,
C2C12 myotubes display a hypertrophic response following
treatment with insulin-like growth factor-1 (IGF-1;
Semsarian et al. 1999). Therefore, to examine the response
of primary human skeletal muscle cell cultures to these
factors, myotubes derived from HSMM and SkMDC were
treated with various concentrations of Dex, Mstn, or IGF-1
for 48 h and then fixed and immuno-stained for MYH2.
Nuclei were visualized by Hoechst-staining. Representative
images of untreated myotubes or those treated with Mstn
(1 μg/ml) or Dex (50 μM) are shown in Fig. 2A and with
IGF-1 (1 μg/ml) are shown in Fig. 2B. HSMM and SkMDC
undergo an atrophy-like response to both Mstn and Dex
treatment, while only HSMM display a hypertrophy-like
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response to IGF-1. Total myotube areas were measured as
described in Semsarian et al. (1999) and Lecomte et al.
(2010) and results were plotted as the percent decrease or
increase in myotube area compared to untreated control
cultures (Fig. 2A, B). The plots show that Mstn and Dex
induced statistically significant decreases in myotube area
over untreated control cultures at all concentrations (except
for the HSMM 250 ng/ml Mstn-treated group which showed
decreased myotube area but failed to reach statistical
significance; Fig. 2A). Quantification of IGF-1 effects on
both cell populations confirmed that only HSMM cultures
responded with a hypertrophic response, with significant
increases in myotube area at 100 and 1,000 ng/ml IGF-1,
(Fig. 2C). Statistical significance, using Student’s t test was
performed by comparing the total myotube area in multiple
untreated cultures with the total myotube area in treated
cultures and then assigning statistical significance (*) if
p<0.05.
Figure 1. HSMM and SkMDC differentiated into multinucleated My-
osin Heavy Chain-2 (MYH2)-positive myotubes. (A) Representative
phase contrast and dark-field images of MYH2-immunostained cells
(green), with Hoechst-labeled nuclei (blue) after 1 d in growth medium
(phase contrast images) or 3 d in differentiation medium (dark-field
images; magnification ×10; scale bar=100 microns). (B) Skeletal
muscle cell marker gene expression by RT-PCR. Plots show gene
expression of early (MYOD, Mef2C) and late (MYOG, TNNT, and
MYH2) muscle cell markers, normalized to B2M gene expression,
relative to expression levels at day 0 (time at which differentiation
media was added to the cells); *p<0.05 vs. day 0 using Student’s t test.
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To examine the signaling pathways that were activated
during these treatments, cell lysates were prepared at the end
of the 48 h treatment period and then probed with antibodies
to phosphorylated- and total Smad2, and phosphorylated-
and total AKT, since these molecules are involved in the
earliest stage responses to the Mstn and IGF-1 ligands
(Rebbapragada et al. 2003; Duan et al. 2010). Upon binding
to cell surface receptors, the myostatin-receptor complex
directly phosphorylates the signaling molecules Smad2 and
Smad3, Rebbrapragada et al. (2003). In both HSMM and
SkMDC, Mstn treatment increased phosphorylated-Smad2
(pSmad2) levels (Fig. 2C) consistent with this ligand’s
known signaling activity described above. In addition, Mstn
reduced the level of phosphorylated-AKT (pAKT) in
HSMM and SkMDC (Fig. 2C). This effect has also been
observed in C2C12 myotubes (McFarlane et al. 2006). Inhi-
bition of AKT phosphorylation is consistent with an atrophic
response, since pAKT activity is a known positive regulator of
muscle protein synthesis and growth (Duan et al. 2010). In
contrast to myostatin, Dex treatment induced downregulation
of the control levels of pSmad2 in SkMDC (Fig. 2C). pSmad2
was not detectable in untreated HSMM cultures, so it is unclear
if Dex affected pSmad2 levels in these cultures. In our studies,
Dex did not affect pAKT levels in either cell population.
Overall, these results suggest that at least for SkMDC, Mstn
and Dex operate through separate pathways to induce an
atrophy-like response. Finally, IGF-1 binding to its receptor is
known to stimulate the phosphorylation of AKT, which stimu-
lates protein synthesis and cell growth (Duan et al. 2010). IGF-
1 treatment of SkMDC, but not HSMM, increased pAKT levels
(Fig. 2C). These results are puzzling since only HSMM, and
not SkMDC, showed a morphological response to IGF-1, with
a substantial increase in myotube area (Fig. 2B). This could be
due to the relatively high pAKT levels in untreated HSMM
compared to SkMDC which may help prime the cells’ hyper-
trophic response to exogenous IGF-1. It is also possible that
IGF-1 acts through an AKT-independent mechanism to induce
a hypertrophy-like response in HSMM and is insufficient to
cause such a response in SkMDC.
In addition to Mstn and Dex, the cytokine TNF-related
weak inducer of apoptosis (TWEAK) has been reported to be
a potent inducer of muscle atrophy (Dogra et al. 2007a) and
blocks the differentiation of C2C12 myoblasts into myotubes
(Dogra et al. 2006, 2007b). In our studies, treatment of
HSMM and SkMDC myotubes with TWEAK had no ob-
servable effects (data not shown). However, when added to
the culture at the start of myotube differentiation, the differ-
entiation of SkMDCwas completely blocked, while it had no
effect on HSMM differentiation (Fig. 3). Expression of the
TWEAK receptor, FN14, has been demonstrated on human
muscle satellite cells (Girgenrath et al. 2006), but it is possi-
ble that FN14 is not expressed by HSMM which would
explain the absence of an effect of TWEAK in these cultures.
We examined FN14 expression in both cell populations by
real-time RT-PCR and found that it was expressed in both
myoblasts and myotubes and showed no changes during
differentiation (data not shown).
Rescue of myostatin-induced atrophy As shown above,
Mstn induced an atrophy-like morphological response in
both HSMM and SkMDC where the myotubes showed a
substantial decrease in size compared to untreated cultures
(Fig. 2A). We and others are working to target myostatin with
inhibitors to block its negative regulation of muscle mass as a
treatment for frailty. One such inhibitor consists of a fusion
between the ligand-binding domain of ActRIIb, the high
affinity receptor for Mstn, and the Fc region of immunoglob-
ulin G (ActRIIb-Fc). This molecule is a potent inhibitor of
Mstn activity in vivo (Lee et al. 2005). To assess its activity in
Figure 3. Effect of TWEAK on HSMM and SkMDC. Representative
images of MYH2/Hoechst-labeled myotubes from cultures differentiat-
ed for 4 d in differentiation medium with TWEAK (1 μg/ml). (Magni-
fication ×10; scale bar=100 microns).
Figure 2. Induction of atrophy and hypertrophy in HSMM and
SkMDC myotubes. (A) Differentiated myotubes were treated with a
concentration series of Mstn or Dex for 48 h. Representative images of
MYH2/Hoechst-labeled myotubes treated with 1 μg/ml Mstn or 50 μM
Dex for 48 h. Plots of the percent decrease, from untreated cells, in
myotube area at each concentration of test agent are shown. (All plots
represent means±SEM, n=15. *p<0.05 vs. untreated using Student’s t
test. All images at ×10 magnification; scale bar=100 microns). (B)
Differentiated myotubes were treated with a concentration series of
IGF-1 for 48 h. Representative images of MYH2/Hoechst-labeled
myotubes following treatment with 1 μg/ml insulin-like growth
factor-1 (IGF-1). Plots show the percent increase, from untreated cul-
tures, in myotube area at each concentration of IGF-1. (All plots
represent means±SEM, n=15. *p<0.05 vs. untreated using Student’s
t test. All images at ×10 magnification; scale bar=100 microns). (C)
Western blots of myotube lysates from cultures treated with 1 μg/ml
Mstn, 50 μM Dex, or 1 μg/ml IGF-1 for 48 h and probed with
antibodies to phosphorylated- and total Smad2 and phosphorylated-
and total AKT. Anti-alpha tubulin was used as a loading control.
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HSMM and SkMDC, myotubes were treated with Mstn in the
presence of various concentrations of ActRIIb-Fc for 48 h.
Images of MYH2-positive myotubes were captured and
myotube areas were quantified as described above. As
expected, the images showed that Mstn alone induced a sig-
nificant decrease in myotube area, and this atrophy-like re-
sponse was blocked by ActRIIb-Fc in both cell populations
(Fig. 4). The rescue of Mstn-induced atrophy by ActRIIb-Fc
was quantified and plotted as the percent change from
untreatedmyotubes (Fig. 4). In both cell populations, 50μg/ml
ActRIIb-Fc induced a significant percent change in area com-
pared to cells treated with Mstn (1 μg/ml) alone (0 μg/ml
ActRIIB-Fc). The plots demonstrated that ActRIIB-Fc
blocked Mstn-induced atrophy in these cultures, such that
the myotube area was significantly different to that measured
in cultures treated withMstn alone. At lower concentrations of
ActRIIb-Fc, statistically significant effects were shown in
SkMDC cultures only, suggesting that these cells were more
sensitive to the rescue effect. Thus, HSMM and SkMDC may
be used to identify and characterize inhibitors of myostatin
activity.
Gene transfer into HSMM and SkMDC The ability to genet-
ically manipulate cells in culture provides powerful tools for
analysis. Hence, various methods of introducing DNA into
HSMM and SkMDC were investigated. Transfection of both
growing cells as well as differentiated myotubes was
attempted. Lipid-mediated transfection reagents were largely
Figure 4. ActRIIB-Fc (a myostatin inhibitor) blocks myostatin-in-
duced atrophy in HSMM and SkMDC. MYH2/Hoechst-labeled
myotubes differentiated for 3 d and then treated with 1 μg/ml
myostatin±a dilution series of ActRIIB-Fc for 48 h. Representative
images of untreated myotubes and those treated with 1 μg/ml Mstn
alone and 1 μg/ml Mstn + 50 μg/ml ActRIIB-Fc. Plot shows the mean
percent change in myotube area from untreated myotubes±SEM, n=15,
*p<0.05 vs 1 μg/ml Mstn using Student’s t test).
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ineffective (we estimated that <20% of the cells were
transfected as assessed by the number of GFP-positive cells),
although HSMM appeared to be slightly more susceptible to
transfection by this method than SkMDC (data not shown).
In addition, we observed that most lipid transfection reagents
significantly slowed down the differentiation of myotubes,
requiring 6 d for full differentiation compared to 2–3 d for
untreated cultures (data not shown). Similar results were
obtained using electroporation methods with the undifferen-
tiated cells (data not shown).
To investigate an alternative method of gene delivery to
HSMM and SkMDC, an adenovirus expressing GFP was used
to infect differentiated myotubes. Myotubes were identified by
staining with anti-MYH2 and detected with Alexa Fluor 555
goat antimouse IgG secondary antibody (red), while the infected
cells were detected by GFP fluorescence (green). Infected
myotubes were orange (red plus green), uninfected myotubes
were red, and infected, undifferentiated cells were green. Al-
though not quantified, it was noted that almost all the myotubes
were orange. In addition, most of the undifferentiated (non-
myotube) cells in the cultures were also successfully infected,
displaying mostly GFP-positive cells (Fig. 5). Finally, undiffer-
entiated cells were also effectively infected by the adenovirus,
although the infection efficiency varied from experiment to
experiment from ∼30% to 80%, quantified by visual inspection
only (data not shown). However, infection of the undifferenti-
ated cells slowed down myotube differentiation by about 3–4 d
(data not shown). In general, adenoviral infection was found to
be the most efficient method for gene delivery into both cell
populations.
Discussion
These studies were performed to screen several commercially
available sources of primary human skeletal myoblasts for
their capacity to reproducibly differentiate into myotubes
and respond appropriately to inducers of atrophy and hyper-
trophy. Out of the four cell types that were screened, only two
demonstrated these features (HSMM from Lonza and
SkMDC from CookMyosite). Although HSMM and SkMDC
both differentiate into myotubes, we observed several marked
differences between them. First, for HSMM there were nota-
bly fewer cell nuclei that were not incorporated into myotubes
after culturing in differentiationmedium compared to SkMDC
(see darkfield images in Fig. 1). This observation could be
explained by a number of factors. For example, although both
cell populations were plated at the same density, differences in
the rate of cell proliferation prior to the induction of differen-
tiation could be responsible, as could different myoblast fu-
sion efficiencies. Alternatively, greater cell death during the 3-d
differentiation period in the HSMM cultures could cause this
effect, or the unincorporated nuclei may represent another cell
type that the SkMDC can generate during differentiation. Sec-
ond, as noted in the results, the organization of nuclei within the
myotubes was different between HSMM and SkMDC. Third,
HSMM and SkMDC showed different responses to some extrin-
sic factors. For example, SkMDC did not undergo a morpholog-
ical hypertrophy response when treated with IGF-1 while
HSMM showed distinct increases in myotube size. We are
currently unable to explain this insensitivity to IGF-1 shown by
SkMDC. Furthermore, we observed that SkMDC were more
sensitive to higher concentrations of Dex. These cells die when
exposed to 100 μM Dex whereas HSMM do not (data not
shown). The finding that Dex had no effect on pAKT levels in
either cell population (see Fig. 2C) was surprising because it
has been shown that Dex treatment reduced pAKT levels in
C2C12 myotubes (Zhao et al. 2009). However, in those ex-
periments, C2C12 myotubes were treated with only 100 nM
Dex overnight. In our studies, myotubes were treated with
50 μM Dex for 48 h. Such culture conditions induced visible
and quantifiable myotube atrophy, whereas 100 nM Dex
failed to induce a visible atrophy. It is possible that the absence
of Dex-regulated pAKT levels in our studies may be due to the
higher Dex concentration and longer incubation time com-
pared to previous studies with C2C12 myotubes, or that this is
a novel feature of primary human skeletal muscle cells.
Finally, the cytokine TWEAK inhibited the differentia-
tion of SkMDC but not HSMM (Fig. 3) and had no effect
on differentiated SkMDC and HSMM myotubes (data not
shown). TWEAK has been shown to induce atrophy in
differentiated C2C12 myotubes (Dogra et al. 2007a) and
prevent the differentiation of C2C12 myoblasts into myotubes
(Dogra et al. 2006, 2007b). However, we are not aware that
similar effects of TWEAK on primary human skeletal muscle
Figure 5. Infection of HSMM and SkMDC with adenovirus. Repre-
sentative images ofMYH2/Hoechst-labeled myotubes differentiated for
2 d and then infected with adeno-GFP at 500 MOI. MYH2 stained red
(Not infected images) in this experiment and adeno-GFP is green. The
overlap results in a yellow/orange color which demonstrates expression
of GFP in MYH2-positive myotubes (Ad-GFP images). (Magnification
×10; scale bar=100 microns).
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cells have been examined. Our findings with TWEAKwere not
explained by the absence of the appropriate TWEAK receptor
(FN14) on these cells, both as myoblasts and myotubes (data
not shown). Therefore, we are unable to explain the absence of
an effect of TWEAK on the differentiation of HSMM and
the absence of TWEAK-induced atrophy in the
myotubes derived from both cell populations at this
time. It is possible that all of these differences may be due
to the origins of the cells. HSMM were derived from the
quadriceps muscle of a young adult male (16 yr old) cadaver,
while SkMDC came from the rectus abdominus muscle of an
older male (52 yr old) living donor. It is possible, even likely,
that the precise characteristics of primary human skeletal
muscle cells will be affected by numerous donor factors, such
as age, gender, and general health. Thus, comparison of results
from experiments using cells from different donors may be
challenging.
During our analyses, we noticed differences in the gene
expression profile for MYOD and MYOG in both cell pop-
ulations compared to what has been published for primary
skeletal muscle cells (Cornelison and Wold 1997; Zammit
et al. 2006). In this work, it was shown that MYOD expres-
sion is typical of a transcription factor with a rapid significant
increase in expression upon commitment of satellite cells to
the muscle lineage. This expression is then followed by rapid
downregulation of expression, at the same time as MYOG
expression is turned on. In our studies, we failed to demon-
strate a significant upregulation of MYOD after 24 h of
culture in differentiation medium. It is possible that MYOD
was upregulated within 10 h and so we were measuring the
down regulation of its expression at 24 h. It is also possible
that both cell populations represent committed muscle pre-
cursors, which already express MYOD, so the fold change in
expression upon switching to differentiation medium would
be minimal. Indeed, the SkMDC vendor (Cook Myosite) has
shown that as myoblasts, these cells already express MYOD
(Janowski 2011). In our cultures, MYOG expression was
maximal between 24 and 48 h in differentiation medium.
Expression of MYOG has been shown as early as 10 h after
switching to differentiation medium, with highest expres-
sion levels seen before 48 and 60 h in differentiation
medium (Bigot et al. 2008). It is possible that our cultures
also upregulate MYOG expression at earlier time-points in
differentiation medium, but we did not harvest RNA at
time-points earlier than 24 h. The prolonged expression
profile of MYOG from the 24 h time-point in our cultures
agrees with what has been shown for primary human muscle
cells (Bigot et al. 2008).
In summary, we have identified two commercially avail-
able sources of primary human skeletal muscle cells that can
reproducibly differentiate into multinucleated myotubes in
culture. Myotube differentiation occurs rapidly upon shifting
the cells into differentiation medium, within 2–3 d, and they
express characteristic molecular markers of muscle differen-
tiation. The myotubes derived from these cells can be induced
to undergo morphological atrophy- and hypertrophy-like re-
sponses. We have also shown that the atrophy response
can be blocked with a pharmacological inhibitor of myostatin,
a known negative regulator of muscle mass. Finally, these
myotubes can be efficiently infected with adenoviruses, pro-
viding a method for genetic modification. Such modifications
would potentially allow adenoviral-shRNA knock-down
screens for muscle atrophy targets which could then be
targeted for inhibition by small or large molecule compounds.
Taken together, our results indicate that these primary human
skeletal muscle cells may be a useful system for studying
skeletal muscle cell differentiation and may also provide tools
for studying new therapeutic molecules such as myostatin
inhibitors.
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